Анализ выживаемости больных периферическим раком легкого после радиочастотной абляции

Lung cancer is the leading cause of cancer death. Surgical resection remains the standard of care, but may not be an option for some patients, due to comorbid illnesses. From 2008 to 2015 123 radiofrequency ablation (RFA) was performed in 98 patients with peripheral non-small cell lung cancer (NSCLC) in the Samara Regional Clinical Oncology Center. Median overall survival was 42 months (95% CI 30,9-53,1). 1, 3 and 5-year survival rates were 89%, 59% and 38%, respectively. Median time to progression was 28 months (95% CI 18,4-37,6), and 1, 3 and 5-year disease-free survival were 77%, 44% and 35% respectively. Thus, radiofrequency ablation may be a good treatment option for patients with inoperable lung cancer.